News
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology ...
More than 170,000 people still sought medical help for acute respiratory infection (ARI), including 22,000 with ...
Viral pneumonia can sometimes stem from viruses that include the flu, common cold, COVID-19 and respiratory syncytial virus (RSV), according to Cleveland Clinic. This type of pneumonia typically ...
The authors assessed the patient characteristics associated with RSV vaccination among older adults hospitalized during the ...
A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates ... funded in part by the US Department of Health and Human Services Biomedical Advanced Research and ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), ...
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
today announced that data from the Company’s Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV) has been accepted for an oral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results